13th Dutch Stem Cell Meeting
2020 at 9:00 am
2020 at 6:00 pm
UMCU, Utrecht, Heidelberglaan 100, 3584 CX
On the 17th of April 2020, the Dutch Society for Stem Cell Research (DSSCR) organizes its 13th annual meeting. The aim of this meeting is to unite researchers from the Dutch stem cell community, thereby promoting exchange of ideas, data and future plans. The DSSCR meeting provides a unique opportunity for PhD-students and young post-docs working on stem cells to present and discuss their work to the Dutch Stem Cell community in selected oral presentations based on submitted abstracts. The three best oral presentations will be awarded a travel grant of €500.
Information & registration
For this symposium, we are delighted to announce the confirmation of three renowned keynote speakers in our field; Pekka Katajisto, Kevin Eggan and Marella De Bruijn. Pekka Katajisto from University of Helsinki, Finland, and Karolinska Institutet, Sweden https://www.katajisto-lab.com/, and Director of the Center of Excellence in Stem Cell Metabolism is renowned for his outstanding research on both stem cell intrinsic, and extrinsic mechanisms altering tissue renewal capacity during aging. Kevin Eggan from the Department of Stem Cell and Regenerative Biology, Harvard University, Boston, MA https://hscrb.harvard.edu/labs/eggan-lab/, did groundbreaking work on creating platforms to increase reproducibility of stem cell and reprogramming technologies with the ultimate goal of improving understanding and treatment of psychiatric diseases. Marella de Bruijn from MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford UK https://www.rdm.ox.ac.uk/about/our-divisions/nuffield-division-of-clinical-laboratory-sciences/nuffield-division-of-clinical-laboratory-sciences-research/de-bruijn-group-developmental-haematopoiesis is renowned about her study on the embryonic origins of blood stem cells with the aim to understand the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.